Company to Provide Update on Clinical and Commercial Development for OPTTX and LUNA TORONTO, Sept. 19 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of medical imaging systems for the operating room, today announced that Dr. Rick Mangat, Vice-President, General Manager, Cardiac and Novadaq Corp., will present the corporate story, technology and highlights, including an update on clinical and commercial development for both the OPTTX(R) and LUNA(TM) Systems, at the UBS Global Life Sciences Conference. The conference runs from Monday, September 25 through Thursday September 28 at the Grand Hyatt New York. Dr. Mangat presents at 4:00 p.m. on Monday, September 25. About Novadaq Technologies Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and ophthalmic diseases and conditions. Novadaq's SPY(R) Intra-operative Imaging System, commercially available worldwide, enables cardiac surgeons to visually assess coronary vasculature and bypass graft functionality during the course of open-heart surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD) by using the same core imaging technology that is used in the SPY System. Novadaq filed for CE Mark approval for the OPTTX System at the end of Q2 2006 and expects a limited launch in Europe by year end. Novadaq's product for urology, LUNA is designed to enable surgeons to visualize nerve bundles during the course of urological procedures such as radical prostatectomy in order to reduce negative outcomes including impotency. For more information, please visit the company's website at www.novadaq.com. Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings; actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. %SEDAR: 00022069E
Novadaq to present at UBS Global Life Sciences Conference
Novadaq Technologies Inc. on 6ix
Earlier from Novadaq Technologies
- Novadaq updates on OPTTX clinical results as presented at this year's joint American Society of Retina Specialists and European Vitreo Retinal Society meeting
- Novadaq Announces European Distribution Contract with Kodak
- Novadaq Announces Luna System as Subject of Best Scientific Paper Award at the World Conference of Endourology
- Novadaq hires Divisional Vice President of Sales, Cardiac
- Novadaq Reports Financial Results For Second Quarter Of 2006
Later from Novadaq Technologies
- Novadaq announces posting of CMS reimbursement recommendation for SPY
- Novadaq announces initiation of LUNA System human clinical trials
- Novadaq to hold third quarter 2006 conference call and webcast
- Novadaq announces CE Mark for OPTTX System
- Novadaq reports financial results for third quarter of 2006
Follow Novadaq Technologies into a list and get an email when it puts out news.
Follow Novadaq Technologies